Healthcare provider profile · identity verified

Robert B Harrington, MD

Family Practice · HUBER HEIGHTS, OH · NPI 1710941513

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	373	105
Lisinopril	Lisinopril	294	83
Levothyroxine Sodium	Levothyroxine Sodium	283	69
Amlodipine Besylate	Amlodipine Besylate	198	52
Hydrochlorothiazide	Hydrochlorothiazide	154	51
Losartan Potassium	Losartan Potassium	154	43
Tamsulosin Hcl	Tamsulosin Hcl	122	33
Metformin Hcl Er	Metformin Hcl	116	30
Omeprazole	Omeprazole	114	34
Metoprolol Succinate	Metoprolol Succinate	110	28
Gabapentin	Gabapentin	108	22
Glimepiride	Glimepiride	104	22
Pantoprazole Sodium	Pantoprazole Sodium	102	24
Sertraline Hcl	Sertraline Hcl	102	24
Meloxicam	Meloxicam	85	30
Albuterol Sulfate Hfa	Albuterol Sulfate	83	22
Simvastatin	Simvastatin	78	19
Rosuvastatin Calcium	Rosuvastatin Calcium	76	24
Lorazepam	Lorazepam	75	19
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	65	14
Montelukast Sodium	Montelukast Sodium	62	16
Clopidogrel	Clopidogrel Bisulfate	56	11
Metformin Hcl	Metformin Hcl	56	16
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	54	suppressed
Alprazolam	Alprazolam	53	suppressed
Finasteride	Finasteride	52	11
Pravastatin Sodium	Pravastatin Sodium	52	15
Duloxetine Hcl	Duloxetine Hcl	51	suppressed
Lovastatin	Lovastatin	51	12
Metoprolol Tartrate	Metoprolol Tartrate	51	13
Allopurinol	Allopurinol	41	11
Carvedilol	Carvedilol	40	suppressed
Bupropion Xl	Bupropion Hcl	37	suppressed
Synthroid	Levothyroxine Sodium	35	12
Jardiance	Empagliflozin	33	suppressed
Buspirone Hcl	Buspirone Hcl	31	suppressed
Furosemide	Furosemide	29	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	29	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	28	21
Potassium Chloride	Potassium Chloride	28	suppressed
Tramadol Hcl	Tramadol Hcl	28	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	25	suppressed
Trazodone Hcl	Trazodone Hcl	25	suppressed
Citalopram Hbr	Citalopram Hydrobromide	24	suppressed
Methocarbamol	Methocarbamol	24	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	24	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	23	suppressed
Cephalexin	Cephalexin	22	18
Methylprednisolone	Methylprednisolone	22	18
Cefuroxime	Cefuroxime Axetil	21	19
Famotidine	Famotidine	21	suppressed
Meclizine Hcl	Meclizine Hcl	21	suppressed
Prednisone	Prednisone	20	suppressed
Amoxicillin	Amoxicillin	19	19
Indapamide	Indapamide	18	suppressed
Clonazepam	Clonazepam	17	suppressed
Januvia	Sitagliptin Phosphate	17	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	17	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	16	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Terbinafine Hcl	Terbinafine Hcl	15	suppressed
Atenolol	Atenolol	14	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	14	suppressed
Ozempic	Semaglutide	14	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Ezetimibe	Ezetimibe	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Valsartan	Valsartan	12	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	11	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Glipizide	Glipizide	11	suppressed
Glipizide Er	Glipizide	11	suppressed
Jantoven	Warfarin Sodium	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed
Vascepa	Icosapent Ethyl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error